Management of foot/ankle osteoarthritis by Australian general practitioners: an analysis of national patient-encounter records

KL Paterson; C Harrison; H Britt; RS Hinman; KL Bennell

Journal article

Management of foot/ankle osteoarthritis by Australian general practitioners: an analysis of national patient-encounter records

KL Paterson, C Harrison, H Britt, RS Hinman, KL Bennell

Osteoarthritis and Cartilage | ELSEVIER SCI LTD | Published : 2018

DOI: 10.1016/j.joca.2018.03.013

Abstract

Objective: To document the management of foot/ankle osteoarthritis/arthritis (OA) by general practitioners (GP) in Australia. Design: We analysed data from the Bettering the Evaluation and Care of Health Program April 2010–March 2016 inclusive. Patient and GP encounter characteristics were extracted. Data were classified by the International Classification of Primary Care, Version 2, and summarised using descriptive statistics and 95% confidence intervals (95% CIs) around point estimates. Results: The dataset included 583,900 patient-encounter records among which foot/ankle OA was managed 621 times, at a rate of 1.1 per 1000 encounters, with an annual estimated 152,000 GP encounters national..

View full abstract

University of Melbourne Researchers

Kade Paterson Author

Rana Hinman Author

Kim Bennell Author

Related Projects (2)

CAN UNLOADING FOOTWEAR IMPROVE CLINICAL CARE OF PEOPLE WITH KNEE OSTEOARTHRITIS?

It is the fourth highest cause of morbidity in Australia and national health expenditure in 2007 was $2.03 billion. Footwear can reduce knee..

MUSCULOSKELETAL PAIN AND DISABILITY: IMPROVING OUTCOMES THROUGH CONSERVATIVE INTERVENTIONS

Musculoskeletal conditions (particularly back pain and osteoarthritis) are highly prevalent and have a major impact on health and well being..

Grants

Awarded by Merck

Funding Acknowledgements

This study was supported by a NHMRC Program Grant (#1091302). KB is partly funded by the National Health and Medical Research Council (NHMRC) and RH is supported by an Australian Research Council Future Fellowship (FT130100175). Between 2010 and 2016 the BEACH program was funded by: AbbVie Pty Ltd, Australian Government Department of Health, Australian Government Department of Veterans' Affairs, AstraZeneca Pty Ltd (Australia), Bayer Australia Ltd, bioCSL (Australia), GlaxoSmithKline Australia Pty Ltd, Merck, Sharp and Dohme (Australia), National Prescribing Service Ltd, Novartis Pharmaceuticals Australia Pty Ltd, Sanofi-Aventis Australia Pty Ltd, Seqirus (Australia) Pty Ltd and Pfizer Australia. The funding bodies had no influence on the conceptualisation, design or conduct of the research, nor on the preparation of this paper.